ause of new information, future events, or otherwise.Contact:American Oriental Bioengineering, Inc.Hong Zhu(646) 367-1765AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(UNAUDITED)SEPTEMBER
30,DECEMBER 31,20112010(RESTATED)CURRENT ASSETSCash and cash equivalents
$
83,018,431
$
94,568,520Restricted Cash654,977537,297Accounts and notes receivable, net64,117,23880,598,919Inventories, net24,201,06612,665,586Advances to suppliers and prepaid expenses19,547,92414,246,144Deferred tax assets221,222649,503Receivable for disposal of investment39,832,54738,567,410Other current assets1,839,8552,986,005Total Current Assets233,433,260244,819,384LONG-TERM ASSETSProperty, plant and equipment, net136,405,433109,547,616Land use rights, net157,892,698155,433,311Other long term assets12,281,3708,167,880Construction in progress32,378,39622,516,044Other intangible assets, net12,858,50914,889,127Investments in and advances to equity investments18,922,08819,179,235Goodwill33,164,12133,164,121Deferred tax assets84,176147,024Unamortized financing costs1,580,7212,359,404Total Long-Term Assets405,567,512365,403,762TOTAL ASSETS$
639,000,772
$
610,223,146LIABILITIES AND SHAREHOLDERS’ EQUITYSEPTEMBER 30,DECEMBER 31,20112010(RESTATED)CURRENT LIABILITIESAccounts payable
$
14,304,039
$
10,716,686Notes payable654,977537,297Other payables and accrued expenses14,987,56418,039,557Taxes payable845,7531,237,169Short-term bank loans12,766,8616,957,258Current portion of long-term bank loans62,47261,405Other liabilities 5,160,5216,284,107Deferred tax liabilities87,382243,304Total Current Liabilities48,869,56944,076,783LONG-TERM LIABILITIESLong-term bank loans, net of current portion631,990679,866Deferred tax liabilities14,263,06615,837,479Unrecognized tax benefits7,874,8026,055,656Convertible Notes109,500,000115,000,000Total Long-Term Liabilities
'/>"/>
SOURCE American Oriental Bioengineering, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 Related medicine technology :1.
American Oriental Bioengineering to Hold Third Quarter 2011 Earnings Conference Call at 8:00 AM on November 15, 20112.
Positive Results from Phase 2 Trial of Mesoblasts Adult Stem Cell Therapy Presented at the American Heart Association Annual Meeting3.
Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH4.
Novation Applauds the IMS Institute for Healthcare Informatics for Calling Attention to the Drug Shortage Crisis Facing American Hospitals5.
Keryx Biopharmaceuticals Announces Highlights from Zerenex™ (ferric citrate) Poster Presentations at American Society of Nephrology Kidney Week 2011 Annual Meeting6.
Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology7.
LX2931 Phase 2 Data to be Presented at the American College of Rheumatology Conference8.
American Oriental Bioengineering Delays Release of its Third Quarter 2011 Financial Results and Earnings Conference Call9.
Adeona Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting10.
Masimo Awarded the American Association of Respiratory Cares 2011 Zenith Award11.
Discovery Labs Releases New AFECTAIR™ Performance Data Presented at the American Association for Respiratory Care Annual Meeting